can you switch from tirzepatide to semaglutide Semaglutide: Safety Guide – PlexusDx Switching from Semaglutide to Tirzepatide

Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) A study published in JAMA Ophthalmology in July 2024 indicates that patients with type 2 diabetes who are taking GLP-1 receptor agonists may be at an increased risk for developing a serious and debilitating condition known as Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

This is based on its 6 to 8 day half-life and the pharmacological principle that 4 to 5 half-lives are required for near-complete elimination

Because of this, there is not much data about the risks over a long time

NOTE: Headaches usually improve over time as the body adjusts to Accutane